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Introduction
Progressive multifocal
leukoencephalopathy (PML) is a rare and
debilitating disease caused by the JC virus
and results in demyelination of
oligodendrocytes and glial cell lysis, leading
to plaque development on the brain and
neurological problems (Gorelik et al., 2011).
PML develops in individuals who have an
immune disorder and who have been
treated with immunomodulatory
medications. Such individuals include those
affected with Multiple Sclerosis (MS)
(Gorelik et al., 2011). MS is a disease that
involves inflammation of the central
nervous system and causes a progressive
decline in neurological function and is
believed to be a result of self-antigens and
an autoimmune response (Keating &
McCormack, 2014). There is no cure for MS
and the majority of cases are classified as
relapse-remitting (Major & Douek, 2013).
The first-line medications used to treat
MS show only a 30% reduction in relapses
per year. Recently a new medication,
Natalizumab, has shown a 68% reduction in
relapses per year (Baldwin & Hogg, 2013).
While Natalizumab shows promise in the
treatment of MS, the drug has shown to
increase the risk of development of PML,
especially in long-term use (more than 18
months) (Schwab et al., 2013). There is no
cure for PML and 30-50% of patients who
develop the disease die within the first few
months of diagnosis. Those that survive, are
typically left with severe neurological
damage (National Institute of Neurological
Disorders and Stroke [NINDS], 2015).
As an Advanced Nurse Practitioner
(ANP), the author will encounter patients
diagnosed with MS, as MS is a fairly
common neurological disorder with 1 in
750 people in the United States at risk for
developing the disease (National Multiple
Sclerosis Society, n.d.). These patients may
be newly diagnosed or looking for new
treatment options. Knowing the risk of PLM,
signs and symptoms and its effects can
assist the ANP and the patient in making an
informed decision about their treatment
options.

Signs and Symptoms
• Signs and symptoms of PML can vary greatly depending on the area of
the brain that is affected (Berger et al., 2013).
• Patients may initially present with distinct behavioral or cognitive
changes that are reported by family members (Fitzgerald, 2015).
• Other neurological symptoms that can occur include hemiplegia,
lethargy, aphasia, anxiety, fatigue, seizures, impaired memory and ataxia
(Fine, Sorbello, Kortepeter, & Scarazzini, 2014).
• The disease continues to progress slowly over time with worsening
symptoms, leading to death or neurological disabilities (NINDS, 2015).
See Figure 1.

References
Significance of Pathophysiology
• The pathophysiology is significant in that many patients diagnosed with MS and
attempting or undergoing immunosuppression therapy may also have the
antibodies for the JC virus which increases their risk of reactivating the infection,
resulting in PML. Therefore, screening and close observation is warranted in the
patient with MS.
• The pathophysiology of the disease assists in diagnosing. The lesions that
develop in the white matter of the brain can often be observed on MRI (see Figure
3), the signs and symptoms come on gradually as the disease spreads throughout
the brain, and cerebral spinal fluid can be analyzed for presence of the JC virus or
antibodies (Berger et al., 2013).
• Patients with MS that had prior immunosuppression therapy or another
underlying immune disorder, develop PML at a rate of 13 to 1,000. The statistics
are significant and warrant antibody testing and diligent surveillance for the JC
virus and PML with attempted or long-term use of natalizumab (Susman, 2015).

Figure 1 retrieved from:
http://nethealthbook.com/articles/progressive
multifocalleukoencephalopathy.php

Underlying Pathophysiology
• PML is thought to be caused by the JC virus. The JC virus was discovered
after virions were observed on the bodies of oligodendrocytes. Although
much has been learned about the virus, there is still a lot that needs to be
discovered to gain a better understanding of the JC virus and PML (White &
Khalili, 2011).
• The JC virus is thought to affect 66-92% of the general population, as
evidence by JC antibody prevalence in populations studied, and is acquired
in childhood (White & Khalili, 2011). Despite the prevalence of JC
antibodies, the actual occurrence of PML is low leading to the conclusion
that the virus is re-activated, after a period of latency, in
immunosuppressed individuals (White & Khalili, 2011).
• The JC virus is transmitted during childhood and is thought to have initial
portal of entries into the tonsils and GI tract. The body’s immune system
fights the virus, defeats the virus, and then the virus enters a latent stage
within the tonsils, bone and/or kidneys. The majority of people infected
with the latent JC virus will never know the virus is there, unless they
develop an autoimmune disorder or take immunosuppressive medications
(White & Khalili, 2011). See Figure 2.
• The latent form of the JC virus can also be found in the bloodstream,
particularly in B lymphocytes and can circulate in the brain (White &
Khalili, 2011).
• Cytokines are released due to the autoimmune response in MS, causing a
reactivation of the JC viral transcription and replication. A PML lesion on
the brain can then develop due to the initial immunosuppression (White &
Khalili, 2011).
• CD8 T cells play an important role in eliminating viruses and controlling
their spread. Natalizumab suppresses T lymphocytes from crossing the
blood-brain barrier, in an effort to control the demyelination in MS, which
may prevent these cells from suppressing the latent JC virus adding to the
reactivation and development of PML (White & Khalili, 2011).
• The resulting development of PML plaques can lead to glial cell lysis and
demyelination leading to neurological signs and symptoms (White &
Khalili, 2011).

Figure 3 retrieved from:
http://pmlconsortium.org/healthcare-professionals/diagnosis

Implications to Nursing Care
• The APN should be aware that any patient presenting with a
history of MS and taking natalizumab, can begin showing signs of
PML at any time, particularly after long-term therapy. The APN
should also be aware that when a patient with a history of MS
presents with new symptoms, there is a chance that the
symptoms may not be a result of MS, but of PML and quick action
is needed (Fitzgerald, 2015).
• Symptoms of MS relapse tends to develop quickly, over hours to
days while PML symptoms occur more slowly (Fitzgerald, 2015).
• MS responds to steroid therapy or levels off, whereas PML
continues to progress despite treatment (Fitzgerald, 2015).
• Most patients with MS are cared for by a specialist, however
APNs may encounter these patients in family practice or even in
the acute care setting and need to be aware of PML and its effects.
Symptom management and attempting to improve quality of life
may be a vital part of the APN’s role when dealing with a patient
with PML.
• APNs in family practice may encounter newly diagnosed
patients with MS and needs to be able to discuss the treatment
options and risks/benefits to assist their client during that
difficult time. Therefore, an understanding of PML and its relation
to MS is important.

Conclusion

Figure 2 retrieved from:
http://www.nature.com/nrneurol/journal/v6/n12/fig_tab/nrneurol.2010.164_F1.
html

The JC virus is a fairly common virus that many people are
unaware they have been infected with and usually remains
dormant for life. However, the virus can be reactivated in certain
immunosuppressive conditions, as in MS and certain
medications for its treatment, causing the development of PML
(Gorelik et al., 2011). PML affects glial cells and creates
lesions/plaques on the brain that can cause severe neurological
disabilities and lead to death. There is no cure for the disease
and treatment focuses on symptom management and attempting
to slow the progression with plasma exchange (NINDS, 2015). A
combination of MRI to look for PML associated lesions,
cerebrospinal fluid analysis for antibodies and signs and
symptoms lead to the diagnosis of PML (Fitzgerald, 2015). The
APN should be aware that PML can develop in patients with MS
and know what signs to look for and when further testing is
needed. If PML is suspected, fast action and referral is needed by
the APN.
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